CAMP4 Therapeutics (NASDAQ:CAMP) CFO Purchases $39,600.00 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CFO Kelly Gold bought 10,000 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were purchased at an average price of $3.96 per share, for a total transaction of $39,600.00. Following the purchase, the chief financial officer owned 10,000 shares in the company, valued at $39,600. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Kelly Gold also recently made the following trade(s):

• On Monday, August 3rd, Kelly Gold purchased 6,551 shares of CAMP4 Therapeutics stock. The shares were acquired at an average cost of $1.65 per share, for a total transaction of $10,809.15.

CAMP4 Therapeutics Price Performance

Shares of NASDAQ:CAMP traded up $0.01 during trading on Wednesday, hitting $3.80. 132,086 shares of the company’s stock were exchanged, compared to its average volume of 268,681. CAMP4 Therapeutics Corporation has a 52-week low of $1.41 and a 52-week high of $7.75. The business’s 50-day simple moving average is $4.11 and its 200 day simple moving average is $4.34. The company has a market cap of $238.45 million, a price-to-earnings ratio of -1.64 and a beta of 0.27.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million for the quarter. On average, sell-side analysts anticipate that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CAMP has been the topic of several research analyst reports. UBS Group set a $15.00 target price on CAMP4 Therapeutics in a research note on Friday, August 14th. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.56.

Institutional Trading of CAMP4 Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CAMP. Bridgeway Capital Management LLC purchased a new position in shares of CAMP4 Therapeutics during the second quarter worth $36,000. Jefferies Financial Group Inc. acquired a new position in CAMP4 Therapeutics in the 4th quarter valued at about $70,000. Bank of America Corp DE acquired a new position in CAMP4 Therapeutics in the 2nd quarter valued at about $78,000. OMERS ADMINISTRATION Corp purchased a new stake in CAMP4 Therapeutics during the fourth quarter worth about $115,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.